Document Detail


How to improve the survival of the kidney transplant - is it only the pharmaceutical management?
MedLine Citation:
PMID:  24617949     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Kidney transplantation is the best treatment option in chronic kidney disease patients. Despite the new potent immunosuppressants, the long-term graft survival has not significantly improved. This is a rather complex issue with interrelationship between pretransplant donor-recipient variables, recipient post-transplant perioperative non/immunological factors, the combination/dose of maintenance immunosuppression and the general noncompliance of the patient. The recipients with an increased immunological risk should be maintained on triple therapy with steroids, preferably tacrolimus (Tac) or cyclosporine (CsA) plus mycophenolate mofetil (MMF). Eventual calcineurin inhibitor (CNI) minimization should be coupled with either protocol biopsies or frequent biochemistry monitoring including periodical assessment of anti-human leukocyte antigen and donor-specific antibodies. Recipients with standard immunological risks may be considered for as low as possible triple immunosuppression (steroids, Tac/CsA, MMF) after a period of 6 - 12 months. In cases of CNI minimization, a modification with a higher dose of the other two drugs in the triple therapy combination might be considered. The nonadherence to the prescribed maintenance therapy should be regularly checked-up. In conclusion, antibody induction, MMF, steroids and low-dose Tac/CsA should be the mainstream therapy in majority of patients. The short- and mid-term encouraging results for CNI minimization/withdrawal seem to correspond to recent findings of chronic antibody-mediated rejection, and long-term results need further evaluation.
Authors:
Goce Spasovski; Jelka Masin-Spasovska
Related Documents :
10903459 - Pyocystis: two case reports of patients in renal failure.
7922179 - Epidemiology and prevention of renal disease.
24043749 - Effect of donor kir2dl1 allelic polymorphism on the outcome of pediatric allogeneic hem...
25476409 - Clinical outcome of renal artery stenting for hypertension and chronic kidney disease u...
15620809 - Primary hyperaldosteronism, a mediator of progressive renal disease in cats.
24206859 - Kidney paired donation and its potential impact on transplantation.
8787449 - Maximal preservation time of tracheal allografts. the paris-sud university lung transpl...
9509559 - Acute renal failure in experimental envenomation with africanized bee venom.
21696039 - Kidney transplantation at ucsf: 8,300 transplants and onward.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-3-11
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  -     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2014 Mar 
Date Detail:
Created Date:  2014-3-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Measurements of pilots' occupational solar UV exposure.
Next Document:  High-Efficient Energy Funneling Based on Electrochemiluminescence Resonance Energy Transfer in Grade...